Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
CRISPR Therapeutics AG (NASDAQ: CRSP)
CRSP Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
18.30%
Analyst Rating:
BUY
Analyst Forecast (1yr):
48.60%
CRSP Stock Analysis
CRSP
PE Ratio:
CRSP
PEG Ratio:
Not Available
CRSP
Forward EPS Growth (12 month):
0.00%
CRSP
PS Ratio:
1224.2
CRSP
PSG Ratio:
4.2
CRSP
Forward Revenue Growth (12 month):
295.00%
CRSP Articles
No data was found